9-aminocamptothecin has been researched along with rubitecan in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.88) | 18.7374 |
| 1990's | 6 (35.29) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nicholas, AW; Wall, ME; Wani, MC | 1 |
| Giovanella, B; Harris, N; Mendoza, J; Pantazis, P | 2 |
| Giovanella, BC; Harris, NJ; Hinz, HR; Natelson, EA | 1 |
| Giovanella, BC | 1 |
| Early, JA; Giovanella, BC; Hinz, HR; Kozielski, AJ; Mendoza, JT; Pantazis, P | 1 |
| Bigg, DC; Lavergne, O | 1 |
| Beijnen, JH; Jansen, S; Rizzo, J; Rosing, H; Schellens, JH; Schoemaker, NE; Schöffski, P | 1 |
| Bates, SE; Gounder, MK; Rajendra, R; Ross, DD; Rubin, EH; Saleem, A; Schellens, JH; Sinko, P | 1 |
| Belani, CP; Egorin, MJ; Fakih, M; Jin, R; Jung, LL; Potter, DM; Ramanathan, RK; Strychor, S; Trump, DL; Walko, C; Zamboni, WC | 1 |
| Egorin, MJ; Eiseman, JL; Hamburger, DR; Jin, R; Joseph, E; Jung, LL; Ramanathan, RK; Strychor, S; Zamboni, WC | 1 |
| Egorin, MJ; Goel, S; Iqbal, T; Mani, S; Parise, RA; Repinski, TV; Strychor, S; Zamboni, WC | 1 |
| Takimoto, CH | 1 |
| Davis, TA; Egorin, MJ; Jung, LL; King, CR; Mani, S; Marsh, S; Maruca, LJ; McLeod, HL; Parise, RA; Potter, DM; Ramanathan, RK; Strychor, S; Zamboni, WC | 1 |
| Herzog, TJ; Wethington, SL; Wright, JD | 1 |
| Chen, P; Huang, C; Li, K; Liu, M; Wang, L; Xue, J; Yan, Z; Zhu, Z | 1 |
| Hamilton, G; Klameth, L; Rath, B; Thalhammer, T | 1 |
2 review(s) available for 9-aminocamptothecin and rubitecan
| Article | Year |
|---|---|
[The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Macromolecular Substances; Mice; Molecular Structure; Neoplasm Proteins; Prodrugs; Structure-Activity Relationship; Topoisomerase I Inhibitors | 1998 |
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
Topics: Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2008 |
4 trial(s) available for 9-aminocamptothecin and rubitecan
| Article | Year |
|---|---|
Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors.
Topics: Administration, Oral; Camptothecin; Drug Administration Schedule; Humans; Neoplasms | 2004 |
Clinical and pharmacokinetic study evaluating the effect of food on the disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Camptothecin; Cross-Over Studies; Fasting; Female; Food; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms | 2006 |
Disposition of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite in relation to ABC transporter genotypes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP-Binding Cassette Transporters; Camptothecin; Female; Genotype; Humans; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Neoplasms; Polymorphism, Single Nucleotide | 2006 |
A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Area Under Curve; Camptothecin; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Time Factors | 2011 |
11 other study(ies) available for 9-aminocamptothecin and rubitecan
| Article | Year |
|---|---|
Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Leukemia L1210; Solubility; Structure-Activity Relationship | 1986 |
The role of pH and serum albumin in the metabolic conversion of 9-nitrocamptothecin to 9-aminocamptothecin by human hematopoietic and other cells.
Topics: Antineoplastic Agents; Camptothecin; Hematopoietic Stem Cells; Humans; Hydrogen-Ion Concentration; Serum Albumin; Tumor Cells, Cultured | 1995 |
Conversion of 9-nitro-camptothecin to 9-amino-camptothecin by human blood cells in vitro.
Topics: Animals; Antineoplastic Agents; Blood Cells; Camptothecin; Cells, Cultured; Humans; Mice; Tumor Cells, Cultured | 1994 |
Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice.
Topics: Administration, Oral; Animals; Camptothecin; Dogs; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Mice; Mice, Nude; Species Specificity; Tissue Distribution | 1994 |
New perspectives in colon cancer chemotherapy.
Topics: Animals; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Mice; Mice, Nude; Neoplasm Transplantation | 1994 |
Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro.
Topics: Animals; Camptothecin; Cell Cycle; Cell Division; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 1993 |
Determination of 9-nitrocamptothecin and its metabolite 9-aminocamptothecin in human plasma using high-performance liquid chromatography with ultraviolet and fluorescence detection.
Topics: Camptothecin; Chromatography, High Pressure Liquid; Humans; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet | 2002 |
Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Division; Dogs; Drug Resistance, Neoplasm; Humans; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Recombinant Fusion Proteins; Selection, Genetic; Transfection; Tumor Cells, Cultured | 2003 |
Relationship between plasma exposure of 9-nitrocamptothecin and its 9-aminocamptothecin metabolite and antitumor response in mice bearing human colon carcinoma xenografts.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Camptothecin; Cell Line, Tumor; Chromatography, High Pressure Liquid; Colonic Neoplasms; Female; HT29 Cells; Humans; Mice; Mice, SCID; Treatment Outcome; Xenograft Model Antitumor Assays | 2005 |
Are there any better camptothecins than the ones we have?
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Resistance, Neoplasm; Humans; Irinotecan; Pancreatic Neoplasms; Research; Topoisomerase I Inhibitors | 2003 |
Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cyclin-Dependent Kinases; Drug Synergism; Enzyme Inhibitors; Humans; Irinotecan; Small Cell Lung Carcinoma; Topotecan | 2014 |